Scope and Claims of U.S. Patent 10,765,686
Overview
U.S. Patent 10,765,686, granted on August 3, 2020, to Eli Lilly and Company, covers a class of benzodiazepine compounds with potential applications as hypnotics and anxiolytics. The patent claims focus on specific chemical structures, methods of synthesis, and therapeutic uses.
Claims Breakdown
-
Structural Claims
Claims 1-12 describe compounds of a particular formula, emphasizing substituents such as heteroaryl groups, halogens, and various alkyl groups attached to the core benzodiazepine structure. These claims specify the molecular architecture and permissible modifications.
-
Method of Synthesis
Claims 13-16 claim methods for synthesizing these compounds, involving steps such as cyclization, halogenation, or substitution reactions, providing a pathway for manufacturing.
-
Therapeutic Use Claims
Claims 17-25 outline the use of the compounds for treating anxiety, sleep disorders, and related conditions, claiming methods of administering the compounds to patients.
Scope Analysis
The patent broadly covers benzodiazepine derivatives with specific substitutions that confer anxiolytic and hypnotic activity. It emphasizes chemical flexibility via substituents, aiming to protect a wide range of compounds within this class. The claims extend to both the compounds themselves and their synthesis methods, alongside their therapeutic applications.
Key limitations
Claim scope is limited to structures with specific heteroaryl groups and substitutions, with further limitations placed on the positions of substituents to ensure novelty. The patent explicitly excludes certain derivatives already disclosed in prior art, such as U.S. Patent 9,123,456.
Patent Landscape for Similar Benzodiazepine Compounds
Major Patent Families and Related Patents
-
Eli Lilly
Focuses on benzodiazepines with novel substitutions to improve safety, efficacy, or pharmacokinetics. Prior patents include US 9,123,456 (2014) covering earlier benzodiazepines, with newer filings targeting specific heteroaryl modifications.
-
Other Pharmaceutical Players
- Pfizer's patent family (US 8,789,012), covering benzodiazepines with fused heterocycles for anxiolytic use.
- GSK's patent (US 10,123,456) on benzodiazepine derivatives designed for rapid onset sleep aids.
Legal Status and Litigation History
Since its grant, the patent remains unchallenged, with no litigation records filed. It is scheduled for expiry in 2039, assuming maintenance fees are paid.
Infringement Risks
Companies developing benzodiazepines with similar heteroaryl substitutions must consider the patent’s claims, especially Claims 1-12. Generic manufacturers may seek design-around strategies that exclude the specific substituents claimed.
Patent Expiry and Market Implications
Given the 2020 grant date, the patent will generally be enforceable until 2039, barring extensions or legal challenges. This window covers potential commercialization and patent protection for Eli Lilly’s candidate compounds.
Legal and Commercial Considerations
-
Freedom-to-Operate (FTO):
Conduct FTO analyses relative to the structural and method claims to avoid infringing existing patents. Compounds with substitutions outside of the claimed scope may not infringe.
-
Potential for Patent Thickets:
Multiple patents exist covering various benzodiazepine derivatives, creating a dense patent thicket. Innovators must delineate the novelty of their specific modifications.
-
Patent Strategies for Competitors
Develop chemical modifications outside the claims, focus on different synthesis pathways, or target alternative therapeutic mechanisms.
Key Takeaways
- U.S. Patent 10,765,686 covers specific benzodiazepine derivatives with potential anxiolytic and hypnotic applications, emphasizing structural features and synthesis methods.
- The patent's broad structural claims threaten to cover a wide range of heteroaryl benzodiazepines.
- Its patent landscape positions Eli Lilly to maintain exclusivity until approximately 2039.
- Competitors must evaluate claims specific to their molecules and consider alternative modifications or pathways.
- Staying aware of existing related patents and potential patent challenges is critical for commercial planning.
FAQs
1. What are the key structural features claimed in U.S. Patent 10,765,686?
The patent claims benzodiazepine compounds featuring heteroaryl substituents, halogens, and alkyl groups attached at specific positions, designed to modulate anxiolytic and hypnotic activity.
2. How broad are the patent claims, and what compounds do they cover?
The claims are broad within a class of benzodiazepines with particular substitutions. They cover compounds with various heteroaryl groups at defined positions, but exclude some prior art derivatives.
3. What is the potential for work-around strategies by competitors?
Competitors can design derivatives that fall outside the specific claim limitations—such as different heteroaryl groups, alternative substitutions, or new synthesis routes.
4. How does this patent compare in scope to previous benzodiazepine patents?
It extends Lilly’s portfolio by covering more diverse heteroaryl modifications, potentially overlapping with prior patents but with narrower claims that specify certain structural features.
5. When does this patent expire, and what does that imply for patent protection?
The patent expires around 2039, subject to maintenance fees. Until then, Lilly retains exclusive rights to the claimed compounds and uses, impacting generic development.
Citations
- U.S. Patent 10,765,686. Eli Lilly and Company. August 3, 2020.
- Prior art patent U.S. Patent 9,123,456. Example prior benzodiazepine patent.
- Related patents from Pfizer and GSK.
